Da humant normalt immunoglobulin er blevet anvendt til behandling af disse sygdomme i nogen tid, og i overensstemmelse med de gældende retningslinjer, var der kun behov for to små undersøgelser for at fastslå virkningen og sikkerheden af Kiovig hos patienter.
As human normal immunoglobulin has been used to treat these diseases for some time, and in accordance with current guidelines, only two small studies were needed to establish the effectiveness and safety of Kiovig in patients.